Search

everythinglearnresearchcommunity

for

Search:↓

The user experienced anxiety and a rapid heartbeat after restarting finasteride at 0.25-0.3 mg, considering whether to continue or stop. They also use minoxidil but did not have these side effects with minoxidil alone.

Topical melatonin may help with inflammation-induced hair loss. The user plans to try it and share results.

PTD-DBM therapy for hair loss is being developed by Dr. Kang-Yell Choi, with human testing planned in South Korea. Some clinics in the U.S. offer PTD-DBM/valproic acid therapy, but it hasn't completed trials yet.

The user is seeking recommendations for a knowledgeable dermatologist in the Denver/Boulder area to address male pattern baldness, as they are dissatisfied with their current treatment of topical finasteride and are considering switching to dutasteride. They feel their current doctor is not open to exploring different treatments that could improve hairline thickness.

A user started taking 1mg of finasteride daily but experienced anxiety and brain fog, considering reducing the dose to 0.5mg to adjust. They seek advice on whether this change could help manage side effects and hair shedding.

Hair loss itch is caused by DHT attacking follicles and stimulating nerves. Finasteride users who respond well don't experience this itch.

The conversation discusses starting finasteride for hair loss, with the original poster noting reduced scalp itching and oiliness after the first week. Users share experiences with different dosages and schedules, concerns about side effects, and the potential impact on prostate cancer detection.

The conversation is about the potential effectiveness of a hair loss treatment called pyrilutamide. One person has been using it since September and reports positive results.

Transitioning from finasteride to Pyrilutamide as a treatment for hair loss, and the potential risks associated with taking such a drug. People have discussed the need to wait at least 6 months in order to assess results, and are willing to risk their health trying this new medication.

The user applies 2ml of a lotion containing 5% minoxidil, 0.3% finasteride, hydrocortisone butyrate, and cetirizine before bed, but it leaves a residue on the scalp. Another user suggests reducing the amount to 1ml, as 2ml results in a high finasteride dosage.

People are discussing the use of the peptide GHK-Cu for hair and skin, with mixed results. Some users have tried it alongside other treatments like adenosine and melatonin, but have not seen significant improvements, and one user stopped due to cost.

PP405 is discussed as a potential hair loss treatment, but its effectiveness and safety are uncertain. Some users express skepticism, while others are hopeful, comparing it to existing treatments like Minoxidil and Finasteride.

The conversation is about trying PTD-DBM for hair loss treatment. Users are curious about its effectiveness and results.

A peptide-based hair loss treatment, PP405, reportedly increased hair density by 62% in 90 days, but these claims are unverified and met with skepticism. Users compared PP405 to Minoxidil and Finasteride, expressing doubts about its effectiveness without more evidence.

People are discussing the anticipated release of PP405 phase 2a results, expected by the end of March, with some skepticism about its effectiveness. There is cautious optimism due to past experiences with similar treatments like Breezula, despite concerns about the lack of presentation at the AAD 2026 conference.

Pelage plans to release phase 2 results and start phase 3 trials for PP405 in 2050, but skepticism remains due to past delays and unfulfilled promises. Users express frustration over the lack of progress in hair loss treatments, mentioning Minoxidil, finasteride, RU58841, CB-03-01, and Fluridil.

Using topical finasteride 0.1%, minoxidil 5%, and melatonin for 7 months reduced hair loss significantly, with increased libido and decreased stress tolerance. The user applies the solution once daily, uses nizoral twice weekly, and takes vitamin D and ZMA supplements.

Pyrilutimide, a treatment for hair loss; it's effectiveness compared to other treatments such as Finasteride and RU58841; and some users’ experiences with the treatment.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

A user started taking 0.5 mg of finasteride daily and noticed watery semen, questioning if it's normal or if they should adjust the dosage. Another user suggested it might indicate reduced fertility and may not improve.

FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.

A 16-year-old researching and trying Pyrilutamide for hair loss treatment, reporting back on side effects experienced after one week of use; the reported side effects included testicle pain, headache, and increased shedding. Libido and sexual performance seemed unaffected.

Lower levels of Ferritin and iron are linked to male pattern baldness. Checking these levels could provide clinical benefits.

Finasteride and Dutasteride used in combination with RU58841 and microneedling, as a treatment for hair loss. There was discussion on progress of the treatment and potential other methods to consider.

Microneedling and Platelet-Rich Plasma (PRP) are equally effective for treating androgenetic alopecia, with no additional benefits from PRP over microneedling. Both treatments are safe and well-tolerated.

The user is considering a second hair transplant or scalp micropigmentation to address thinning in the crown area and hide scars from a previous transplant. They have been using finasteride and minoxidil for three years but are concerned about the appearance of their donor area and the effectiveness of scalp micropigmentation.

The user started using Pyrilutamide 5% for hair loss and has not experienced side effects after two days. They previously had side effects from Fluridil and topical Minoxidil 5%, and their hair continued thinning with topical Spironolactone.

A 24-year-old male experiencing diffused thinning discusses his DHT levels and hair density issues. He has not used finasteride or dutasteride and is considering AR inhibitors.

A 23-year-old shared progress pictures after five months on Finasteride, starting with 0.25mg and increasing to 1mg, reporting no side effects and noticeable hair improvement. The user is satisfied with the results and plans to continue the treatment, while others in the conversation discuss dosage, side effects, and alternative treatments.

The conversation discusses a user's 7-month progress with hair loss treatment using oral Propecia (finasteride), topical Minoxidil, and a weekly use of a Drama Pen. Some users ask for details about the Drama Pen, while others make jokes or congratulate the user on their progress.